2023 Nobel Prize in Medicine goes to mRNA vaccine pioneers

Nobel Prize in Medicine for the parents of the mRNA vaccine

The Swedish Academy awarded the Nobel Prize in Physiology or Medicine to Hungarian biochemist Katalin Karikó and American immunologist Drew Weissman for developing the messenger RNA technology that made the Pfizer and Moderna elbichito vaccines possible. Karikó spent four decades working in obscurity before her discovery became the basis of the injections administered to billions of people. She is the thirteenth woman to receive the Nobel Prize in Medicine. The announcement has quickly sparked a debate that goes far beyond the laboratory: from the vindication of scientific work to suspicion about the interests surrounding the award.

What exactly is the Swedish Academy rewarding?

The Nobel recognizes the technique that allows messenger RNA to be introduced into cells so the body produces a specific protein. That platform, developed over years by Karikó and Weissman, is what BioNTech and Moderna later used to manufacture their vaccines. It is not a specific commercial product being rewarded, but a line of research that, according to the committee, has had an enormous impact on global health. Some point out that it is usual to wait decades to see whether a discovery holds up, and that here the decision came with unusual estimulante ilegal. The material itself stresses that the technique could lead to many future developments, not just vaccines.

The biggest business in history, according to critics

Part of the discussion claims the prize consecrates an unprecedented business. The argument is that the vaccines were bought en masse by Western governments regardless of price and that adverse effects were covered up. From that viewpoint, the Nobel would be recognition of a product that has not been shown to work against a disease which, they claim, has not been proven to exist or to differ from the flu. The accusation is serious and is not backed by evidence in the material: it is an opinion circulating in the debate, not an established fact. What is a fact is that the public purchases were made without auction and the spending was astronomical.

The Nobel's track record: from Kissinger to lobotomy

Parallels with other awards come up again and again. People recall that the Nobel Peace Prize went to Henry Kissinger, to Barack Obama just days after taking office, and to Menachem Begin. Also that the Nobel Prize in Medicine once rewarded lobotomy, a technique later abandoned that prompted calls for the posthumous withdrawal of the award. The list of contested laureates includes Yasir Arafat and Simon Peres. The conclusion some draw is that the Nobel is not pure meritocracy but narrative: a prize that works for certain power groups and sometimes gets it right and sometimes not.

Robert Malone's shadow and the uncomfortable question

The name of Robert Malone appears in the debate, a researcher who claims a foundational role in messenger RNA technology and who is not among the winners. The question of why some are included and others not runs through several messages, although no one provides documentation that settles the distribution of credit. What is debated is the Academy's criterion: whether it rewards the foundational paper or the final impact, and whether factors unrelated to science weigh in that calculation. The official answer is not in the material, so the controversy remains open.

The dystopian future some anticipate

One message imagines how this will be told in textbooks thirty-five years from now: the vaccine that saved millions of lives, the work of Karikó and Weissman, and deniers as a footnote. Others reply that this narrative is precisely the problem: the construction of an official story that turns into heroes those who took part in an opaque business. The discussion drifts toward distrust of international institutions —the UN, the WHO, NATO, the EU— to which a single agenda is attributed. These are unproven claims that the article cannot endorse, but they explain why a scientific prize has ended up as a political battleground.

---

The Swedish Academy's decision is made. What is not settled is the discussion over what exactly that recognition means: an unquestionable scientific breakthrough, a multimillion-dollar business, or both at once. The available evidence suggests messenger RNA technology will keep bearing fruit, but also that trust in major prizes is no longer restored with a press release.